SMALL CELL LUNG CANCER

This study is for people with extensive-stage small-cell lung cancer who have already completed their first round of chemotherapy and immunotherapy (durvalumab) without their cancer getting worse. It aims to see if adding a new drug called tarlatamab to their ongoing durvalumab t…

This study is testing a new combination of immune-boosting drugs for people with advanced cancers whose disease has progressed after treatment with standard immunotherapies like pembrolizumab or nivolumab. It aims to see if adding a drug called NAI to other treatments can help sh…

This early-stage trial is testing a new oral medication called BBI-355, both alone and in combination with other drugs, for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to find safe doses and see if the treatment can shrink…

This study is testing a new drug called HPN328, both alone and in combination with other cancer drugs, for people with advanced cancers that have a specific marker called DLL3. The main goals are to find safe and effective doses and to see how well the treatments work. The trial …

This trial is testing if adding chest radiation therapy to a maintenance immunotherapy drug (durvalumab) can better control advanced small cell lung cancer. Patients first receive standard chemotherapy combined with durvalumab. If the cancer responds or stays stable, they then re…

This study is testing a new oral medication called AL8326 for people with recurrent small cell lung cancer who need a second or later line of treatment. The main goals are to find the safest and most effective dose and to see if the drug helps shrink tumors. The trial will involv…

This study is testing a new drug called BNT327, given alongside standard chemotherapy, for people with a fast-growing type of lung cancer called small-cell lung cancer. It is for two groups: people who have not yet received treatment for their advanced cancer, and people whose ca…

This study is testing an oral medication called Abemaciclib for people with certain aggressive lung cancers that have either not responded to standard chemotherapy or have come back after treatment. The goal is to see if the drug can shrink tumors and control the cancer's growth …

This study is testing whether adding two immunotherapy drugs (monalizumab and durvalumab) to standard chemotherapy helps people with small cell lung cancer live longer without their cancer getting worse. It includes two groups: people with newly diagnosed advanced cancer and peop…

This study is testing an experimental drug called XmAb20717 in adults with advanced rare cancers that have few treatment options. The main goals are to see if the drug is safe and if it can shrink tumors or slow their growth. The trial is currently suspended and is not enrolling …

This large, late-stage trial is testing whether adding immunotherapy drugs (durvalumab alone or with tremelimumab) after standard chemoradiation can help patients with limited-stage small cell lung cancer live longer without their cancer worsening. The study involves about 730 pa…

This early-stage trial is testing whether giving chest radiation followed by one of three immunotherapy drug regimens can help control advanced small cell lung cancer for longer. It is for patients whose cancer has stopped growing or shrunk after initial chemotherapy. The main go…

This study is testing a three-drug combination for adults with advanced small cell or non-small cell lung cancer whose initial treatment is no longer working. The first part of the study aims to find the safest and most effective dose. The second part will see how well this combi…

This study is testing whether a two-drug combination (AZD2811 and durvalumab) can help control extensive stage small-cell lung cancer when given as ongoing 'maintenance' therapy after initial chemotherapy. The trial involves about 31 adults whose cancer hasn't worsened after firs…

This is a very early, first-in-human study to check the safety and side effects of an experimental treatment called AMG 119 in adults with small cell lung cancer that has come back or stopped responding to standard chemotherapy. AMG 119 is a type of CAR T-cell therapy, where a pa…

This large Phase 3 trial is testing whether adding the drug lurbinectedin to standard maintenance therapy (atezolizumab) helps people with extensive-stage small-cell lung cancer live longer without their cancer getting worse. The study involves 660 participants whose cancer respo…

This study is testing whether combining two existing drugs—nivolumab (an immunotherapy) and temozolomide (a chemotherapy)—can help control cancers that have come back or stopped responding to standard treatments. It is for adults with recurrent small-cell lung cancer or advanced …

This study is observing how well the immunotherapy drug atezolizumab works and its safety for patients with advanced lung, bladder, or liver cancer in real-world medical settings. It involves over 2,700 patients who are already receiving this drug as part of their standard care. …